GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » Forward PE Ratio

IntelliPharmaCeutics International (TSXV:IPCI) Forward PE Ratio : 0.00 (As of May. 21, 2024)


View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International Forward PE Ratio?

IntelliPharmaCeutics International's Forward PE Ratio for today is 0.00.

IntelliPharmaCeutics International's PE Ratio without NRI for today is 0.00.

IntelliPharmaCeutics International's PE Ratio for today is 0.00.


IntelliPharmaCeutics International Forward PE Ratio Historical Data

The historical data trend for IntelliPharmaCeutics International's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Forward PE Ratio Chart

IntelliPharmaCeutics International Annual Data
Trend 2015-12 2016-12 2017-07
Forward PE Ratio
20.41 11.85 23.70

IntelliPharmaCeutics International Quarterly Data
2015-12 2016-03 2016-06 2016-09 2016-12 2017-03
Forward PE Ratio 20.41 3.07 2.16 8.74 11.85 35.46

Competitive Comparison of IntelliPharmaCeutics International's Forward PE Ratio

For the Biotechnology subindustry, IntelliPharmaCeutics International's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Forward PE Ratio falls into.



IntelliPharmaCeutics International Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


IntelliPharmaCeutics International  (TSXV:IPCI) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


IntelliPharmaCeutics International Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines